Biotheranostics→Hologic
Acquisition · Cash · HOLX · announced Jan 5, 2021
Announced
Jan 5, 2021
Closed
Feb 22, 2021
Economics
Cash()
Pre-deal · pre-deal mark: 2021, year precision · Hologic 8-K filing, SEC EDGAR — implied pre-deal valuation
~$230M subject to working capital adjustments
Target
Biotheranostics
Breast Health · Diagnostic / genomic
HQ San Diego, CA · Founded 2006
Molecular diagnostic tests for breast and metastatic cancers (Breast Cancer Index, CancerTYPE ID)
- Hologic investor relations - press release (Jan 5, 2021)
- Business Wire - acquisition completion (Feb 22, 2021)
Acquirer
Hologic (HOLX)
Breast Health
HQ Marlborough, MA
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Entry into oncology growth market — Breast Cancer Index guides post-surgery treatment decisions for breast cancer patients
Evidence ladder
Primary (regulatory / filing)
Hologic 8-K filing, SEC EDGAR (Jan 5, 2021)
SEC EDGAR filings (ticker locator)Secondary (press / IR)
Hologic investor relations press release (Jan 5, 2021)
Secondary (press / IR)
Business Wire (Feb 22, 2021)
Limitations
- ~$230M subject to working capital adjustments
- Pre-deal valuation sourced from: Hologic 8-K filing, SEC EDGAR — implied pre-deal valuation. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Breast Health
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| SuperSonic Imagine | Hologic | Jun 21, 2019 | same evidence class · same acquirer | |
| Faxitron Bioptics | Hologic | Jul 31, 2018 | same evidence class · same acquirer | |
| Endomagnetics | Hologic | May 20, 2024 | same acquirer | |
| Focal Therapeutics | Hologic | Sep 26, 2018 | same acquirer |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Immunomedics | Gilead Sciences | Sep 13, 2020 |
Other verified deals by Hologic
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| Gynesonics | Hologic | Sep 15, 2024 | Gynecological Surgery | |
| Bolder Surgical | Hologic | Oct 14, 2021 | Gynecological Surgery | |
| Acessa Health | Hologic | Aug 25, 2020 | Gynecological Surgery | |
| Gen-Probe | Hologic | Apr 30, 2012 | Diagnostics |
Patient empowerment context
Empowerment context — Biotheranostics
Curated survey mappingHLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.
- Not recommended genetic testing (NCCN: almost all should) (Company / product site)37%cited HLTH 2022Mapping source →
- No survivorship care plan after active treatment (Clinical trial / publication)54%cited HLTH 2022Mapping source →
- Not aware of survivorship resources (Company / product site)2 in 3cited HLTH 2022Mapping source →
Other curated mappings on these gaps: Endomagnetics, Genomic Health, Foundation Medicine, Flatiron Health
Full cited gap matrix →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.